EN 2001
Alternative Names: EN-2001Latest Information Update: 08 Jul 2022
At a glance
- Originator Enosi Life Sciences
- Class Anti-inflammatories; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Intercellular signalling peptide and protein inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer; Inflammation